Overview

Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The duration of dual antiplatelet treatment (i.e. asprin and clopidogrel) after drug-eluting stent implantation is highly debated. This study will evaluate the value of extending such treatment up to 2 years after the procedure as compared to conventional treatment according to our national health institute guidelines (i.e. minimum 1 month after bare metal stent and 6 months after drug-eluting stent) on the composite endpoint of death, MI or stroke.
Phase:
Phase 4
Details
Lead Sponsor:
Marco Valgimigli
Treatments:
Albumin-Bound Paclitaxel
Aspirin
Clopidogrel
Everolimus
Paclitaxel
Purinergic P2Y Receptor Antagonists
Sirolimus
Ticlopidine